[{"quiz_id": "ABMS20260101_kimi-k2-thinking_p05", "question_id": "ABMS20260101_kimi-k2-thinking_p05-001", "question": "A 62-year-old man develops painful hepatomegaly, ascites, and jaundice 3 weeks after completing 6 cycles of FOLFOX adjuvant chemotherapy for colon cancer. Total bilirubin is 8.2 mg/dL, ALT 450 U/L, INR 1.8. Liver biopsy shows sinusoidal congestion, hepatocyte necrosis zone 3, and absence of portal inflammation. What is the definitive therapy?", "options": ["A) High-dose methylprednisolone 1 mg/kg/day and diuretics", "B) Defibrotide 25 mg/kg/day IV in divided doses for 21 days", "C) Transjugular intrahepatic portosystemic shunt (TIPS) placement", "D) N-acetylcysteine 150 mg/kg IV bolus then continuous infusion", "E) Urgent liver transplant evaluation"], "answer": "B", "answer_index": 1, "explanation": "Severe sinusoidal obstruction syndrome from oxaliplatin requires defibrotide, which restores thrombomodulin expression and promotes fibrinolysis. TIPS is contraindicated due to diffuse sinusoidal injury; steroids are ineffective. Transplant is reserved for fulminant hepatic failure with encephalopathy.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "abms_specialty": "Gastrointestinal", "abms_source": "target_topic", "source_label_raw": "Gastrointestinal", "source_quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "source_question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-004", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251221T010349114Z_kimi-k2-thinking_seed131", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251221T010349114Z_kimi-k2-thinking_seed131.jsonl", "pred": "B", "model_outputs": "The clinical presentation of painful hepatomegaly, ascites, and jaundice, combined with the history of recent oxaliplatin-based chemotherapy (FOLFOX) and liver biopsy findings of sinusoidal congestion and zone 3 necrosis, is diagnostic of Sinusoidal Obstruction Syndrome (SOS), formerly known as Veno-Occlusive Disease (VOD).\n\n1.  Diagnosis: Oxaliplatin is a well-established cause of hepatic sinusoidal injury. While often subclinical (\"blue liver\"), it can manifest as overt SOS/VOD. The biopsy findings (sinusoidal congestion, necrosis, lack of inflammation) distinguish it from hepatitis or other etiologies.\n2.  Disease Severity: The patient has severe SOS, evidenced by significant hyperbilirubinemia (8.2 mg/dL) and coagulopathy (INR 1.8).\n3.  Treatment:\n    *   Defibrotide (Option B) is the correct and definitive therapy for severe hepatic SOS/VOD. It is an oligonucleotide with local antithrombotic, anti-inflammatory, and fibrinolytic effects that protect the endothelium. The dosing regimen listed (25 mg/kg/day IV in divided doses for a minimum of 21 days) matches the standard approved labeling for severe VOD/SOS (specifically approved for post-HSCT with renal/pulmonary dysfunction, but it is the standard of care for severe SOS of any etiology in a board exam context).\n    *   TIPS (Option C) is sometimes used to manage portal hypertension symptoms (ascites) in VOD, but it is contraindicated or very high-risk in patients with severe liver dysfunction (indicated by high bilirubin of 8.2 mg/dL) due to the risk of precipitating liver failure and severe encephalopathy. Like listing for transplant, it is not the first-line *medical* therapy for the underlying pathology.\n    *   Steroids (Option A) and N-acetylcysteine (Option D) are not the standard definitive treatments for SOS.\n    *   Liver transplant (Option E) is a consideration if medical therapy fails, but Defibrotide is the first-line intervention to reverse the endothelial injury.\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p05", "question_id": "ABMS20260101_kimi-k2-thinking_p05-002", "question": "A 48-year-old woman with systemic sclerosis presents with NYHA class IV dyspnea. Right heart catheterization: mPAP 52 mmHg, PAWP 6 mmHg, PVR 11 WU. Lung biopsy shows diffuse capillary proliferation within alveolar septa without cellular atypia. She fails to respond to epoprostenol and macitentan. Which intervention is associated with the greatest 5-year survival in this rare WHO Group 1' pulmonary hypertension subset?", "options": ["Switch to inhaled treprostinil 54 μg four times daily", "Add selexipag 1600 μg twice daily", "Initiate combination immunosuppression with cyclophosphamide", "Refer for bilateral lung transplantation", "Perform balloon pulmonary angioplasty"], "answer": "D", "answer_index": 3, "explanation": "Pulmonary capillary hemangiomatosis (PCH) is refractory to all PAH-targeted therapies (A, B) and immunosuppression (C). Balloon angioplasty (E) is contraindicated due to diffuse microvascular disease. Bilateral lung transplantation (D) offers the only survival benefit, with 5-year survival approaching 60% in selected patients, far exceeding the <20% survival on medical therapy alone.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pulmonary", "abms_specialty": "Pulmonary", "abms_source": "topics_mapped", "source_label_raw": "pulmonology", "source_quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "source_question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-009", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251205T080918850Z_kimi-k2-thinking_seed123", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251205T080918850Z_kimi-k2-thinking_seed123.jsonl", "pred": "D", "model_outputs": "The patient's clinical presentation and biopsy findings are characteristic of Pulmonary Capillary Hemangiomatosis (PCH), which is closely related to Pulmonary Veno-Occlusive Disease (PVOD). Both are classified under WHO Group 1' (a distinct subgroup of Pulmonary Arterial Hypertension).\n\n1.  Diagnosis: The key histological finding is \"diffuse capillary proliferation within alveolar septa,\" which defines PCH. The hemodynamic profile (high mPAP, normal PAWP, high PVR) confirms pre-capillary pulmonary hypertension.\n2.  Clinical Context: The patient has systemic sclerosis (a known association) and severe functional impairment (NYHA class IV).\n3.  Treatment Response: She has failed to respond to epoprostenol (the most potent parenteral prostacyclin) and macitentan. In patients with PCH/PVOD, pulmonary vasodilators (like prostacyclins and endothelin receptor antagonists) must be used with extreme caution due to the risk of precipitating life-threatening pulmonary edema. The fact that she has failed these therapies without improvement (and potentially with worsening status) indicates medical refreshery disease.\n4.  Intervention:\n    *   Vasodilators (Options A and B): Switching to inhaled treprostinil or adding selexipag is unlikely to provide benefit after failing IV epoprostenol and carries a high risk of pulmonary edema in PCH/PVOD.\n    *   Immunosuppression (Option C): While immunosuppression (e.g., cyclophosphamide) may be considered in PVOD/PCH associated with *inflammatory* connective tissue diseases (like SLE or Mixed CTD), it is generally not effective in systemic sclerosis-associated vascular disease or idiopathic PCH.\n    *   Balloon Pulmonary Angioplasty (Option E): This is the treatment for Chronic Thromboembolic Pulmonary Hypertension (CTEPH, WHO Group 4), not Group 1 or 1' PAH.\n    *   Lung Transplantation (Option D): Due to the poor prognosis of PCH/PVOD and the lack of effective pharmacologic therapies (and the risks associated with them), lung transplantation is the definitive treatment and the only intervention that offers a significant survival benefit for eligible patients, specifically those in NYHA class III/IV who are non-responders to medical therapy. Current guidelines recommend early referral for transplant evaluation upon diagnosis of PVOD/PCH.\n\nThe answer is (D)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p05", "question_id": "ABMS20260101_kimi-k2-thinking_p05-003", "question": "A 55-year-old immunocompetent gardener develops subacute onset of severe headaches, focal seizures, and left hemiparesis over 3 weeks. Brain MRI shows multiple ring-enhancing lesions with surrounding edema. CSF demonstrates lymphocytic pleocytosis (120 cells/μL) but bacterial, fungal, and mycobacterial cultures are negative. What is the most appropriate empiric therapy?", "options": ["A) Liposomal amphotericin B", "B) Albendazole plus miltefosine", "C) Vancomycin plus ceftriaxone plus dexamethasone", "D) Ganciclovir plus foscarnet", "E) Voriconazole"], "answer": "B", "answer_index": 1, "explanation": "Balamuthia mandrillaris, a free-living amoeba, causes granulomatous encephalitis in immunocompetent individuals with soil exposure, presenting as ring-enhancing lesions mimicking brain abscess or tuberculosis. The combination of albendazole and miltefosine is the recommended treatment. Amphotericin B is used for Acanthamoeba, while voriconazole treats fungal infections. The antiviral combination is for CMV encephalitis.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "abms_specialty": "Infectious Disease", "abms_source": "topics_mapped", "source_label_raw": "Infectious Disease", "source_quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "source_question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-009", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251205T080918850Z_kimi-k2-thinking_seed124", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251205T080918850Z_kimi-k2-thinking_seed124.jsonl", "pred": "B", "model_outputs": "This patient presents with a subacute clinical course (3 weeks), neurological deficits (seizures, hemiparesis), and brain imaging showing multiple ring-enhancing lesions. The cerebrospinal fluid (CSF) profile shows lymphocytic pleocytosis with removal of common bacterial, fungal, and mycobacterial causes (negative cultures).\n\nKey features of the vignette point to Granulomatous Amebic Encephalitis (GAE) caused by _Balamuthia mandrillaris_:\n1.  Epidemiology: The patient is immunocompetent and a gardener. _Balamuthia mandrillaris_ is a free-living ameba found in soil. Unlike _Acanthamoeba_, which typically affects immunocompromised hosts, _Balamuthia_ affects immunocompetent individuals and immunocompromised individuals roughly equally.\n2.  Clinical Course: The presentation is subacute to chronic usually developing over weeks to months, distinguishing it from the hyperacute Primary Amebic Meningoencephalitis (PAM) caused by _Naegleria fowleri_.\n3.  Imaging: MRI findings of multiple ring-enhancing lesions with edema are classic for GAE (often mimicking brain metastasis, abscesses, or tuberculomas).\n4.  Diagnostics: Routine cultures are negative. Diagnosis usually requires tissue biopsy (showing trophozoites) or PCR/metagenomic sequencing.\n\nTreatment Analysis:\nCurrent CDC recommendations and expert consensus for the treatment of GAE involving _Balamuthia_ or _Acanthamoeba_ involve a combination regimen.\n*   Miltefosine is the critical component of the regimen that has improved survival rates in recent years. It is an antiparasitic drug (originally for Leishmaniasis) with activity against free-living amebas.\n*   The recommended cocktail often includes albendazole, fluconazole (or voriconazole), a macrolide (azithromycin/clarithromycin), and sometimes sulfadiazine, flucytosine, and pentamidine. Albendazole is included for its penetration into the CNS and activity against the ameba.\n\nLet's evaluate the options:\n*   A) Liposomal amphotericin B: This is the cornerstone therapy for _Naegleria fowleri_ (PAM) and severe fungal infections. While sometimes used in GAE regimens, _Balamuthia_ is often resistant or less responsive to Amphotericin B compared to _Naegleria_. It is not the most specific answer for subacute GAE.\n*   B) Albendazole plus miltefosine: This option targets the specific etiology (free-living amebas causing GAE). Both drugs are key components of the recommended multi-drug regimen for _Balamuthia_.\n*   C) Vancomycin plus ceftriaxone plus dexamethasone: This is empiric treatment for acute bacterial meningitis. The subacute course, lymphocytic pleocytosis, and negative cultures make this incorrect.\n*   D) Ganciclovir plus foscarnet: This is treatment for CMV encephalitis, typically seen in severely immunocompromised patients (e.g., AIDS with CD4 < 50).\n*   E) Voriconazole: This is the treatment of choice for _Aspergillus_. While fungal abscess is a differential diagnosis, the specific \"gardener\" history and immunocompetent status with this specific presentation strongly favors _Balamuthia_.\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p05", "question_id": "ABMS20260101_kimi-k2-thinking_p05-004", "question": "A 7-year-old girl with McCune-Albright syndrome (confirmed GNAS R201C mutation) presents with premature thelarche, vaginal bleeding, and a growth velocity of 12 cm/year. Bone age is 10 years. Which endocrine intervention specifically targets the underlying pathophysiology of precocious puberty in this condition?", "options": ["GnRH agonist (leuprolide) 7.5 mg IM monthly", "Aromatase inhibitor (letrozole) 2.5 mg daily", "Estrogen receptor antagonist (tamoxifen) 10 mg twice daily", "Progesterone-only contraceptive (medroxyprogesterone) 10 mg daily", "Ketoconazole 200 mg twice daily"], "answer": "B", "answer_index": 1, "explanation": "In McCune-Albright syndrome, precocious puberty results from autonomous ovarian hyperfunction, not central activation. GnRH agonists are ineffective because the process is gonadotropin-independent. Aromatase inhibitors block peripheral estrogen synthesis from autonomous follicular cysts. Tamoxifen is less effective and has more side effects. Progesterone doesn't address estrogen excess. Ketoconazole has significant toxicity.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "abms_specialty": "Pediatrics", "abms_source": "target_topic", "source_label_raw": "Pediatrics", "source_quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "source_question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-003", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251219T234603131Z_kimi-k2-thinking_seed128", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251219T234603131Z_kimi-k2-thinking_seed128.jsonl", "pred": "B", "model_outputs": "Here is the step-by-step reasoning for the correct answer:\n\n1.  Diagnosis: The patient has McCune-Albright syndrome (MAS), evidenced by the classic triad (though only two are needed for diagnosis) of fibrous dysplasia (implied by the syndrome name/bone age issues, though not explicitly detailed, the genetic confirmation is definitive), café-au-lait spots (implied), and hyperfunctioning endocrine disorders. Specifically, she presents with peripheral precocious puberty (PPP), characterized by premature thelarche, vaginal bleeding, and advanced bone age. The *GNAS* R201C mutation leads to constitutive activation of the Gs$\\alpha$ protein.\n\n2.  Pathophysiology: In the ovaries of girls with MAS, the constitutively active Gs$\\alpha$ increases cAMP levels, which mimics FSH signaling. This results in the autonomous (gonadotropin-independent) formation of ovarian cysts and the subsequent overproduction of estrogen (estradiol).\n\n3.  Analysis of Options:\n    *   A. GnRH agonist (leuprolide): This is the treatment for *central* precocious puberty (CPP). While patients with MAS can develop secondary central puberty due to skeletal age advancement, the primary defect is peripheral. GnRH agonists are ineffective for the autonomous ovarian cysts driving the primary presentation.\n    *   B. Aromatase inhibitor (letrozole): The mutation causes upregulation of the aromatase enzyme (CYP19A1) via the cAMP pathway, leading to excess conversion of androgens to estrogens. Aromatase inhibitors specifically block this step, preventing estrogen synthesis. Letrozole is a potent third-generation aromatase inhibitor and is currently considered a first-line pharmacological treatment to prevent bone age advancement and reduce vaginal bleeding in girls with MAS.\n    *   C. Estrogen receptor antagonist (tamoxifen): This agent blocks the effects of estrogen at the receptor. While effective and used in cases where aromatase inhibitors fail or are unavailable, the \"physiological\" target of reducing the autonomous *production* of the hormone is best achieved by aromatase inhibitors. Additionally, current guidelines and literature (e.g., UpToDate, Endocrine Society) often prioritize letrozole or fulvestrant, whereas tamoxifen is generally an alternative.\n    *   D. Progesterone-only contraceptive: While progestins can suppress gonadotropins, they do not effectively treat the autonomous cysts in MAS and are not the specific intervention for the pathophysiology.\n    *   E. Ketoconazole: This is a broad inhibitor of steroidogenesis (mostly adrenal and gonadal) often used in Cushing syndrome or male testotoxicosis. It has significant hepatotoxicity and is not the standard treatment for MAS-associated puberty in girls.\n\n4.  Conclusion: The treatment that specifically targets the synthesis of the hormone driving the symptoms (excess estrogen from aromatase overexpression) is the aromatase inhibitor.\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p05", "question_id": "ABMS20260101_kimi-k2-thinking_p05-005", "question": "A 35-year-old presents with refractory shock (BP 70/40) and bradycardia (HR 40) after ingesting 10 g of sustained-release verapamil. High-dose insulin euglycemic therapy (HIET) is initiated. What is the optimal insulin dosing and monitoring frequency?", "options": ["0.5-1 unit/kg/hr; check glucose every 2 hours", "1-10 units/kg/hr; check glucose every hour", "0.1-0.5 units/kg/hr; check potassium every 4 hours", "5-20 units/kg/hr; check lactate every 2 hours", "2-5 units/kg/hr; check pH every 4 hours"], "answer": "B", "answer_index": 1, "explanation": "HIET for severe calcium channel blocker overdose requires supraphysiologic insulin doses of 1-10 units/kg/hr to overcome insulin resistance and maximize myocardial glucose uptake. Blood glucose must be monitored hourly to maintain euglycemia (150-200 mg/dL) with concurrent dextrose infusion. Lower doses are ineffective. Doses exceeding 10 units/kg/hr are not standard practice. Potassium and pH are monitored but glucose is the critical parameter.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Emergency Medicine", "abms_specialty": "Emergency Medicine", "abms_source": "topics_mapped", "source_label_raw": "Emergency Medicine", "source_quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "source_question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-008", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251205T080918850Z_kimi-k2-thinking_seed125", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251205T080918850Z_kimi-k2-thinking_seed125.jsonl", "pred": "B", "model_outputs": "Analysis of the Clinical Scenario:\nThe patient has ingested a massive, potentially lethal dose of verapamil (10 g) and is in refractory shock with bradycardia. Calcium channel blocker (CCB) toxicity causes myocardial depression and vasodilation. The metabolic hallmark is hyperglycemia and hypoinsulinemia (due to blockage of pancreatic calcium channels). However, the heart shifts from using free fatty acids to carbohydrates under stress, rendering it energy-starved.\n\nHigh-dose Insulin Euglycemic Therapy (HIET):\n*   Mechanism: Insulin acts as a potent positive inotrope, increases myocardial glucose uptake, and improves perfusion.\n*   Dosing: Current toxicology guidelines recommend a bolus of 1 unit/kg followed by an infusion starting at 1 unit/kg/hr. If the hemodynamic response is inadequate, the dose should be titrated up. Maintenance rates often range from 1 to 10 units/kg/hr to achieve hemodynamic stability.\n*   Monitoring: The primary risks are hypoglycemia and hypokalemia.\n    *   Glucose: Blood glucose must be monitored very frequently (typically every 30–60 minutes initially) to maintain euglycemia (usually utilizing a dextrose infusion). Checking every 2 hours (Option A) is unsafe during the initiation and titration phase.\n    *   Potassium: Potassium should be monitored hourly initially, as insulin shifts potassium intracellularly.\n\nEvaluation of Options:\n*   A. 0.5-1 unit/kg/hr is a conservative starting range but sets a ceiling too low for refractory shock in a massive overdose. Furthermore, checking glucose every 2 hours is insufficient for safety.\n*   B. 1-10 units/kg/hr represents the correct therapeutic range for severe toxicity, allowing for necessary titration. Checking glucose every hour is the standard requirement to prevent iatrogenic hypoglycemia and brain injury.\n*   C. 0.1-0.5 units/kg/hr is the dosing range for DKA/HHS or standard glycemic control, not the inotropic doses required for CCB toxicity.\n*   D & E. Specific dose ranges here are arbitrary or subsets of the larger range, but the monitoring parameters (Lactate, pH) are not the immediate safety priorities compared to glucose and potassium.\n\nTherefore, Option B describes the appropriate aggressive dosing strategy and the strict monitoring required for patient safety.\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p05", "question_id": "ABMS20260101_kimi-k2-thinking_p05-006", "question": "A 30-year-old G2P1 at 32 weeks gestation presents with fetal hydrops and mirror syndrome. Which pathophysiologic mechanism best explains her severe preeclampsia-like features?", "options": ["Massive fetomaternal hemorrhage causing maternal anemia", "Placental edema releasing soluble fms-like tyrosine kinase-1 (sFlt-1)", "Maternal antibody production against fetal Rh antigens", "Amniotic fluid embolism triggering systemic inflammation", "Mirror syndrome is a misdiagnosis; this is atypical HELLP"], "answer": "B", "answer_index": 1, "explanation": "Mirror syndrome involves placental edema that mechanically compromises uteroplacental perfusion and releases anti-angiogenic factors like sFlt-1, creating a preeclampsia phenotype. Resolution occurs within 48 hours of delivery or fetal therapy that reduces hydrops.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Obstetrics and Gynecology", "abms_specialty": "Obstetrics and Gynecology", "abms_source": "topics_mapped", "source_label_raw": "obstetrics", "source_quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "source_question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-005", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251205T080918850Z_kimi-k2-thinking_seed126", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251205T080918850Z_kimi-k2-thinking_seed126.jsonl", "pred": "B", "model_outputs": "Here is the step-by-step reasoning for the answer:\n\n1.  Definition of Mirror Syndrome (Ballantyne Syndrome): This is a rare condition where maternal edema, hypertension, and proteinuria develop in association with fetal hydrops. The mother's condition \"mirrors\" the fluid retention of the fetus.\n\n2.  Pathophysiology: The underlying pathophysiology of mirror syndrome is closely related to that of preeclampsia. Both conditions involve placental dysfunction. In cases of fetal hydrops, the placenta often becomes enlarged and edematous (placentomegaly).\n\n3.  Role of Anti-angiogenic Factors: The large, edematous placenta experiences relative ischemia or hypoxia. In response, the placental trophoblasts overproduce anti-angiogenic factors, specifically soluble fms-like tyrosine kinase-1 (sFlt-1).\n\n4.  Mechanism of Action: sFlt-1 enters the maternal circulation and binds to vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), preventing them from interacting with their endothelial receptors. This leads to systemic maternal endothelial dysfunction, which manifests clinically as the triad of hypertension, proteinuria, and massive edema seen in mirror syndrome.\n\n5.  Evaluating the other options:\n    *   A: Massive fetomaternal hemorrhage can cause fetal hydrops (via anemia), but it is the etiology of the hydrops rather than the direct mechanism of the maternal preeclamptic features.\n    *   C: Maternal antibodies (Rh isoimmunization) are a cause of immune hydrops, but the antibodies themselves do not directly cause the maternal endothelial damage; the placental response to the hydrops does.\n    *   D: Amniotic fluid embolism presents with sudden cardiorespiratory collapse, not the subacute development of edema and hypertension.\n    *   E: Mirror syndrome is a distinct and recognized clinical entity, although it is pathophysiologically similar to preeclampsia.\n\nTherefore, the release of anti-angiogenic factors like sFlt-1 from the edematous placenta is the best explanation for the maternal symptoms.\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p05", "question_id": "ABMS20260101_kimi-k2-thinking_p05-007", "question": "A 35-year-old male in a personal injury lawsuit reports severe chronic pain despite normal examinations and imaging. He is observed to be inconsistent in his symptom presentation between evaluations. Which specific criterion best distinguishes malingering from factitious disorder in this scenario?", "options": ["Presence of secondary gain", "Intentional production of symptoms", "Lack of insight into psychological factors", "Symptoms are under voluntary control", "Absence of medical explanation"], "answer": "A", "answer_index": 0, "explanation": "Both malingering and factitious disorder involve intentional symptom production. The key distinction is motivation: malingering seeks external reward (money, avoiding work), while factitious disorder seeks the 'sick role' for psychological needs. Both have insight and voluntary control. Absence of medical explanation is common to both somatic symptom disorders.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "abms_specialty": "Psychiatry", "abms_source": "target_topic", "source_label_raw": "Psychiatry", "source_quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "source_question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-020", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251219T234603131Z_kimi-k2-thinking_seed128", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251219T234603131Z_kimi-k2-thinking_seed128.jsonl", "pred": "A", "model_outputs": "Here is the step-by-step application of the medical knowledge required to answer this question:\n\n1.  Analyze the Conditions:\n    *   Malingering: Involves the intentional production or exaggeration of physical or psychological symptoms. The motivation is to obtain external incentives (secondary gain), such as financial compensation, avoiding work/duty, or obtaining drugs.\n    *   Factitious Disorder: Also involves the intentional production of symptoms. However, the motivation is to assume the sick role (primary gain) to receive medical attention and sympathy. Crucially, there are no obvious external rewards (like money or legal avoidance).\n\n2.  Evaluate the Scenario:\n    *   The patient is involved in a \"personal injury lawsuit,\" which implies a chase for financial compensation.\n    *   There is \"intentional\" deception implied by the inconsistency and normal findings (though Somatic Symptom Disorder also presents with normal findings, the inconsistency and the context of a lawsuit strongly suggest faking).\n    *   Since both Malingering and Factitious Disorder involve the intentional production of symptoms (voluntary control), choices B and D are incorrect as they characterize *both* conditions and do not distinguish between them.\n    *   Choice E (Absence of medical explanation) is a feature of both conditions (as well as somatic symptom disorders) and does not distinguish between them.\n\n3.  Identify the Distinguishing Feature:\n    *   The specific criterion that separates Malingering from Factitious Disorder is the motivation behind the deception.\n    *   Malingering is driven by secondary gain (external rewards like money from the lawsuit).\n    *   Factitious Disorder is driven by the internal need to play the patient role (absence of secondary gain).\n\nTherefore, the presence of secondary gain (the lawsuit/financial compensation) best distinguishes malingering in this case.\n\nThe answer is (A)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p05", "question_id": "ABMS20260101_kimi-k2-thinking_p05-008", "question": "A 68-year-old man presents with a 2-year history of progressive sleep dysfunction characterized by dream enactment, nocturnal stridor, and daytime somnolence. He has developed gait instability and mild cognitive decline. Polysomnography reveals non-REM parasomnias and REM sleep behavior disorder. CSF studies are normal, and brain MRI shows mild cerebellar atrophy. Which antibody is most likely associated with this syndrome?", "options": ["A) Anti-Hu antibody", "B) Anti-Yo antibody", "C) Anti-IgLON5 antibody", "D) Anti-Ma2 antibody", "E) Anti-NMDA receptor antibody"], "answer": "C", "answer_index": 2, "explanation": "Anti-IgLON5 disease is a tauopathy characterized by severe sleep dysfunction (non-REM parasomnias, REM behavior disorder), bulbar symptoms, gait instability, and cognitive decline, often with normal CSF and nonspecific MRI findings. Anti-Hu and Anti-Yo are associated with limbic encephalitis and paraneoplastic cerebellar degeneration respectively. Anti-Ma2 causes diencephalic syndrome, and anti-NMDA receptor encephalitis presents with psychiatric symptoms and characteristic CSF abnormalities.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurology", "abms_specialty": "Neurology", "abms_source": "topics_mapped", "source_label_raw": "Neurology", "source_quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "source_question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-001", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251205T080918850Z_kimi-k2-thinking_seed124", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251205T080918850Z_kimi-k2-thinking_seed124.jsonl", "pred": "C", "model_outputs": "This clinical scenario describes the classic presentation of anti-IgLON5 disease, a distinct neurological disorder characterized by a unique sleep disorder and neurodegeneration.\n\nKey Features Identified in the Scenario:\n1.  Sleep Dysfunction: The hallmark of anti-IgLON5 disease is a complex sleep disorder involving both REM sleep behavior disorder (RBD) (dream enactment) and non-REM parasomnias relative to the same patient.\n2.  Nocturnal Stridor: This is a highly characteristic and distinguishing feature of the disease, resulting from laryngeal dystonia or vocal cord paresis. It can lead to respiratory failure.\n3.  Motor and Cognitive Symptoms: Patients often present with gait instability (ataxia or parkinsonism), bulbar dysfunction (dysphagia, dysarthria), and mild cognitive decline.\n4.  Neuropathology: Unlike typical autoimmune encephalitides, this condition is a tauopathy, linking autoimmune mechanisms with neurodegeneration.\n\nAnalysis of Options:\n*   A) Anti-Hu: Associated with paraneoplastic sensory neuronopathy and encephalomyelitis (often with small cell lung cancer), but not this specific sleep phenotype.\n*   B) Anti-Yo: Associated with paraneoplastic cerebellar degeneration, typically in women with gynecological or breast cancers.\n*   C) Anti-IgLON5: Matches the unique combination of parasomnias, stridor, and gait instability perfectly.\n*   D) Anti-Ma2: Associated with limbic, diencephalic, and brainstem encephalitis (often in young men with testicular tumors). while it causes excessive daytime sleepiness (narcolepsy-like), it does not typically present with the specific stridor and mixed parasomnias described.\n*   E) Anti-NMDA receptor: Associated with psychiatric symptoms, seizures, and dyskinesias, primarily in younger patients.\n\nThe answer is (C)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p05", "question_id": "ABMS20260101_kimi-k2-thinking_p05-009", "question": "A 2-month-old infant with congenital lymphocytic choriomeningitis virus (LCMV) infection presents with chorioretinitis, hydrocephalus, and periventricular calcifications. Which neuroimaging finding best distinguishes LCMV from congenital cytomegalovirus infection?", "options": ["Periventricular calcifications", "Cortical malformations", "Cerebellar hypoplasia", "Temporal lobe cysts", "Lissencephaly"], "answer": "C", "answer_index": 2, "explanation": "While both LCMV and CMV can cause periventricular calcifications, LCMV characteristically causes severe cerebellar hypoplasia due to selective infection of the external granular layer cells. CMV more commonly causes cortical malformations, temporal lobe cysts, and lissencephaly. This distinction is critical for prognosis and genetic counseling, as LCMV has a higher risk of severe neurodevelopmental disability.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "abms_specialty": "Pediatrics", "abms_source": "target_topic", "source_label_raw": "Pediatrics", "source_quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "source_question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-004", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251219T234603131Z_kimi-k2-thinking_seed128", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251219T234603131Z_kimi-k2-thinking_seed128.jsonl", "pred": "D", "model_outputs": "The question identifies a clinical scenario of a 2-month-old infant with congenital lymphocytic choriomeningitis virus (LCMV) infection, highlighting features such as chorioretinitis, hydrocephalus, and periventricular calcifications. The question asks for the neuroimaging finding that best distinguishes LCMV from congenital cytomegalovirus (CMV) infection.\n\n1.  Shared Features: Both congenital LCMV and congenital CMV infections are TORCH infections that share several overlapping neuroimaging and clinical features.\n    *   Periventricular calcifications (Option A) are a hallmark of both CMV and LCMV. (In contrast, Toxoplasmosis typically presents with diffuse, scattered parenchymal calcifications).\n    *   Cortical malformations (Option B) such as pachygyria, polymicrogyria, and neuronal migration disorders are seen in both infections.\n    *   Cerebellar hypoplasia (Option C) is a documented feature of both CMV and LCMV, though some sources note it may be particularly severe in certain LCMV cases. However, it is not a specific discriminator as it occurs frequently in CMV as well.\n    *   Lissencephaly (Option E) or agyria/pachygyria is a type of cortical malformation that can be associated with both, though CMV is classically associated with polymicrogyria.\n\n2.  Distinguishing Feature:\n    *   Temporal lobe cysts (Option D) (specifically anterior temporal subependymal cysts) are a highly characteristic and specific neuroimaging finding associated with congenital CMV infection. They are not typically described as a feature of LCMV infection.\n    *   Therefore, the presence of temporal lobe cysts strongly suggests CMV, while their absence (in the presence of other compatible findings like periventricular calcifications) leaves LCMV as a probable diagnosis. The presence of these cysts is the most reliable binary discriminator among the options provided.\n\nAdditionally, clinically, LCMV is more often associated with macrocephaly (due to obstructive hydrocephalus), whereas CMV is typically associated with microcephaly. However, among the specific neuroimaging options listed, temporal lobe cysts are the distinct feature of CMV that LCMV lacks.\n\nThe answer is (D)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p05", "question_id": "ABMS20260101_kimi-k2-thinking_p05-010", "question": "A 2-month-old infant presents with heart failure, mitral regurgitation, and echocardiographic finding of retrograde flow in a dilated left coronary artery during diastole. Which additional echocardiographic finding is pathognomonic for anomalous left coronary artery from pulmonary artery (ALCAPA)?", "options": ["Left ventricular dilation", "Papillary muscle dysfunction", "Septal wall motion abnormalities", "Coronary artery collaterals with 'seagull' sign", "Right coronary artery dilation"], "answer": "D", "answer_index": 3, "explanation": "In ALCAPA, extensive intercoronary collaterals develop with characteristic bidirectional flow seen on color Doppler as a 'seagull' sign. While LV dilation, papillary muscle dysfunction, and RCA dilation are seen, they are not pathognomonic. The seagull sign represents collaterals from RCA to LCA with flow reversal into PA, which is diagnostic of ALCAPA.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "abms_specialty": "Pediatrics", "abms_source": "target_topic", "source_label_raw": "Pediatrics", "source_quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "source_question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-013", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251219T234603131Z_kimi-k2-thinking_seed128", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251219T234603131Z_kimi-k2-thinking_seed128.jsonl", "pred": "D", "model_outputs": "This question describes a classic presentation of Anomalous Left Coronary Artery from the Pulmonary Artery (ALCAPA), also known as Bland-White-Garland syndrome. The infant presents with heart failure typically around 2 months of age as pulmonary vascular resistance drops, leading to a \"steal\" phenomenon where blood flows from the myocardium *into* the pulmonary artery rather than from the aorta to the myocardium.\n\nAnalysis of the Options:\n\n*   A. Left ventricular dilation: This is a consistent finding (due to dilated cardiomyopathy from ischemia) but is non-specific. It can be seen in viral myocarditis, idiopathic DCM, and other conditions.\n*   B. Papillary muscle dysfunction: ALCAPA frequently causes ischemia and infarction of the anterolateral papillary muscle, leading to mitral regurgitation (mentioned in the stem). While characteristic—especially if the muscle appears hyperechogenic (bright)—dysfunction alone is a consequence of the ischemia and is not strictly pathognomonic compared to visualizing the anomaly itself.\n*   C. Septal wall motion abnormalities: This is a sign of ischemia but is non-specific.\n*   E. Right coronary artery dilation: This is a very strong supportive finding. The RCA dilates to supply collateral blood flow to the LCA territory. However, a dilated RCA can also be seen in coronary artery fistulas (e.g., RCA to RA/RV) or pulmonary atresia with intact ventricular septum (RVDCC). Therefore, while highly suggestive, it is not pathognomonic for the *origin* of the LCA from the PA.\n*   D. Coronary artery collaterals with 'seagull' sign: The definitive diagnosis of ALCAPA relies on demonstrating the anomalous origin. The left main coronary artery typically bifurcates into the Left Anterior Descending (LAD) and Circumflex (LCx) arteries. This bifurcation has a shape resembling a seagull in flight. In ALCAPA, this \"seagull\" structure is visualized arising from the pulmonary artery rather than the aorta. The presence of extensive intercoronary collaterals (often seen as color flow signals within the ventricular septum) provides the retrograde flow that fills this vessel, allowing the \"seagull\" (the LCA bifurcation) to be visualized at the PA with flow exiting into the PA. The combination of septal collaterals and the visualization of the bifurcating vessel at the PA (Seagull sign) is pathognomonic.\n\nThe term \"Seagull sign\" in this context refers to the specific appearance of the LCA bifurcation associated with the anomalous connection and collateral flow.\n\nThe answer is (D)"}]